The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Insulin Resistance Promotes Parkinson’s Disease through Aberrant Expression of α-Synuclein, Mitochondrial Dysfunction, and Deregulation of the Polo-Like Kinase 2 Signaling
Open accessAbstract
Background: Insulin resistance (IR), considered a hallmark of diabetes at the cellular level, is implicated in pre-diabetes, results in type 2 diabetes, and negatively affects mitochondrial function. Diabetes is increasingly associated with enhanced risk of developing Parkinson’s disease (PD); however, the underlying mechanism remains unclear. This study investigated the probable culpability of IR in the pathogenesis of PD. Methods: Using MitoPark mice in vivo models, diabetes was induced by a high-fat diet in the in vivo models, and IR was induced by protracted pulse-stimulation with 100 nM insulin treatment of neuronal cells, in vitro to determine the molecular mechanism(s) underlying altered cellular functions in PD, including mitochondrial dysfunction and α-synuclein (SNCA) aberrant expression. Findings: We observed increased SNCA expression in the dopaminergic (DA) neurons of both the wild-type and diabetic MitoPark mice, coupled with enhanced degeneration of DA neurons in the diabetic MitoPark mice. Ex vivo, in differentiated human DA neurons, IR was associated with increased SNCA and reactive oxygen species (ROS) levels, as well as mitochondrial depolarization. Moreover, we demonstrated concomitant hyperactivation of polo-like kinase-2 (PLK2), and upregulated p-SNCA (Ser129) and proteinase K-resistant SNCA proteins level in IR SH-SY5Y cells, however the inhibition of PLK2 reversed IR-related increases in phosphorylated and total SNCA. Similarly, the overexpression of peroxisome proliferator-activated receptor-γ coactivator 1-alpha (PGC)-1α suppressed ROS production, repressed PLK2 hyperactivity, and resulted in downregulation of total and Ser129-phosphorylated SNCA in the IR SH-SY5Y cells. Conclusions: These findings demonstrate that IR-associated diabetes promotes the development and progression of PD through PLK2-mediated mitochondrial dysfunction, upregulated ROS production, and enhanced SNCA signaling, suggesting the therapeutic targetability of PLK2 and/or SNCA as potential novel disease-modifying strategies in patients with PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, insulin resistance affects the clearance of Aβ, the hyperphosphorylation of tau, and glucose metabolism and enhances the aberrant expression of α-syn.356,357”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [357]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: A shared comparison of diabetes mellitus and neurodegenerative disorders
Morsi, M., Maher, A., Aboelmagd, O., Johar, D., & Bernstein, L. H. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26261 · Cited by 55
RetractedDeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611 · cited 1×
“Impaired cellular response to insulin, known as insulin resistance (IR), is a hallmark of type 2 diabetes and contributes to the systemic downstream detrimental effects of diabetes [2].”
BackgroundRisk of dementia in diabetes mellitus: a systematic review
Biessels, G. J., Staekenborg, S., Brunner, E., Brayne, C., & Scheltens, P. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70284-2 · Cited by 2,187
Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums
Arnold, S. E., Arvanitakis, Z., Macauley-Rambach, S. L., Koenig, A. M., Wang, H.-Y., Ahima, R. S., Craft, S., Gandy, S., Buettner, C., Stoeckel, L. E., et al. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.185 · Cited by 1,597
Tansey, M. G., & Goldberg, M. S. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.004 · Cited by 1,045
Copps, K. D., & White, M. F. (2012) · Diabetologia · doi:10.1007/s00125-012-2644-8 · Cited by 1,017 · cited 2×
“Mechanistically, since increased p85α expression and IRS1 serine phosphorylation are essential for the induction of clinically-apparent IR [32], we demonstrated significant increase in the p-IRS1/IRS1 ratio (123%, p < 0.”
BackgroundPARIS (ZNF746) Repression of PGC-1α Contributes to Neurodegeneration in Parkinson's Disease
Shin, J.-H., Ko, H. S., Kang, H., Lee, Y., Lee, Y.-I., Pletinkova, O., Troconso, J. C., Dawson, V. L., & Dawson, T. M. (2011) · Cell · doi:10.1016/j.cell.2011.02.010 · Cited by 953
Quantitative Analysis of Histological Staining and Fluorescence Using ImageJ
Jensen, E. C. (2013) · The Anatomical Record · doi:10.1002/ar.22641 · Cited by 941
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889 · cited 1×
“Furthermore, several anti-glycemic agents, including exenatide, a glucagon-like peptide analogue, have exerted a disease-modifying effect on PD; exenatide is presently in phase III clinical trial as a neuroprotective drug for patients with PD [18,19].”
BackgroundNeuroinflammation in Parkinson's disease and its potential as therapeutic target
Wang, Q., Liu, Y., & Zhou, J. (2015) · Translational Neurodegeneration · doi:10.1186/s40035-015-0042-0 · Cited by 884
PGC-1 α, A Potential Therapeutic Target for Early Intervention in Parkinson’s Disease
Zheng, B., Liao, Z., Locascio, J. J., Lesniak, K. A., Roderick, S. S., Watt, M. L., Eklund, A. C., Zhang-James, Y., Kim, P. D., Hauser, M. A., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001059 · Cited by 857
Biochemical and cellular properties of insulin receptor signalling
Haeusler, R. A., McGraw, T. E., & Accili, D. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.89 · Cited by 739
Is Alzheimer’s disease a type 3 diabetes? A critical appraisal
Kandimalla, R., Thirumala, V., & Reddy, P. H. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.08.018 · Cited by 621
α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson’s disease
Di Maio, R., Barrett, P. J., Hoffman, E. K., Barrett, C. W., Zharikov, A., Borah, A., Hu, X., McCoy, J., Chu, C. T., Burton, E. A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf3634 · Cited by 619
Exenatide and the treatment of patients with Parkinson's disease
Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68295 · Cited by 529
Dehay, B., Bourdenx, M., Gorry, P., Przedborski, S., Vila, M., Hunot, S., Singleton, A., Olanow, C. W., Merchant, K. M., Bezard, E., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00006-x · Cited by 529
Ludtmann, M. H. R., Angelova, P. R., Horrocks, M. H., Choi, M. L., Rodrigues, M., Baev, A. Y., Berezhnov, A. V., Yao, Z., Little, D., Banushi, B., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04422-2 · Cited by 513
Type 2 Diabetes and the Risk of Parkinson's Disease
Hu, G., Jousilahti, P., Bidel, S., Antikainen, R., & Tuomilehto, J. (2007) · Diabetes Care · doi:10.2337/dc06-2011 · Cited by 466
Schapira, A. H. V., Olanow, C. W., Greenamyre, J. T., & Bezard, E. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61010-2 · Cited by 392
An Overview of Murine High Fat Diet as a Model for Type 2 Diabetes Mellitus
Heydemann, A. (2016) · Journal of Diabetes Research · doi:10.1155/2016/2902351 · Cited by 366
Insulin resistance in the nervous system
Kim, B., & Feldman, E. L. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2011.12.004 · Cited by 321 · cited 1×
“Impaired mitochondrial biogenesis, depolarization of mitochondrial membrane potential, and increased reactive oxygen species (ROS) have been reported in neuronal cells with IR [16].”
BackgroundMitochondrial and lysosomal biogenesis are activated following PINK 1/parkin‐mediated mitophagy
Ivankovic, D., Chau, K., Schapira, A. H. V., & Gegg, M. E. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13412 · Cited by 264 · cited 2×
“Chau (Institute of Neurology, University College London, London, UK) [23].”
BackgroundSelf-citationAssociation between diabetes and subsequent Parkinson disease: A record-linkage cohort study
De Pablo-Fernandez, E., Goldacre, R., Pakpoor, J., Noyce, A. J., & Warner, T. T. (2018) · Neurology · doi:10.1212/wnl.0000000000005771 · Cited by 242
Polo-like Kinase 2 (PLK2) Phosphorylates α-Synuclein at Serine 129 in Central Nervous System
Inglis, K. J., Chereau, D., Brigham, E. F., Chiou, S.-S., Schöbel, S., Frigon, N. L., Yu, M., Caccavello, R. J., Nelson, S., Motter, R., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.c800206200 · Cited by 240
Wang, X., Becker, K., Levine, N., Zhang, M., Lieberman, A. P., Moore, D. J., & Ma, J. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0696-4 · Cited by 211
Biomarkers of insulin sensitivity and insulin resistance: Past, present and future
Park, S. E., Park, C.-Y., & Sweeney, G. (2015) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2015.1023429 · Cited by 203
Oueslati, A., Schneider, B. L., Aebischer, P., & Lashuel, H. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309991110 · Cited by 203
Altered mitochondrial function in insulin-deficient and insulin-resistant states
Ruegsegger, G. N., Creo, A. L., Cortes, T. M., Dasari, S., & Nair, K. S. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120843 · Cited by 202
Diabetes and the Risk of Developing Parkinson’s Disease in Denmark
Schernhammer, E., Hansen, J., Rugbjerg, K., Wermuth, L., & Ritz, B. (2011) · Diabetes Care · doi:10.2337/dc10-1333 · Cited by 198
Mollenhauer, B., Zimmermann, J., Sixel‐Döring, F., Focke, N. K., Wicke, T., Ebentheuer, J., Schaumburg, M., Lang, E., Friede, T., Trenkwalder, C., et al. (2019) · Movement Disorders · doi:10.1002/mds.27492 · Cited by 191
Sripetchwandee, J., Chattipakorn, N., & Chattipakorn, S. C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00496 · Cited by 190
Risk of Parkinson Disease Onset in Patients With Diabetes
Sun, Y., Chang, Y.-H., Chen, H.-F., Su, Y.-H., Su, H.-F., & Li, C.-Y. (2012) · Diabetes Care · doi:10.2337/dc11-1511 · Cited by 185
Nuclear localization and phosphorylation modulate pathological effects of alpha-synuclein
Pinho, R., Paiva, I., Jerčić, K. G., Fonseca-Ornelas, L., Gerhardt, E., Fahlbusch, C., Garcia-Esparcia, P., Kerimoglu, C., Pavlou, M. A. S., Villar-Piqué, A., et al. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddy326 · Cited by 180
Mitochondrial dynamics in Parkinson's disease: a role for α-synuclein?
Pozo Devoto, V. M., & Falzone, T. L. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.026294 · Cited by 177
Samuel, F., Flavin, W. P., Iqbal, S., Pacelli, C., Sri Renganathan, S. D., Trudeau, L.-E., Campbell, E. M., Fraser, P. E., & Tandon, A. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.705095 · Cited by 169
PGC-1α, glucose metabolism and type 2 diabetes mellitus
Wu, H., Deng, X., Shi, Y., Su, Y., Wei, J., & Duan, H. (2016) · Journal of Endocrinology · doi:10.1530/joe-16-0021 · Cited by 167
Neurodegeneration in an animal model of Parkinson’s disease is exacerbated by a high-fat diet
Morris, J. K., Bomhoff, G. L., Stanford, J. A., & Geiger, P. C. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00449.2010 · Cited by 163 · cited 4×
“As already alluded, diabetes was induced by feeding C57BL/6 mice a high-fat diet for two months; an approach which enhances the loss of DA neurons in toxin-induced Parkinsonism, in vivo [30].”
BackgroundMethodInfluentialImaging insights into basal ganglia function, Parkinson's disease, and dystonia
Stoessl, A. J., Lehericy, S., & Strafella, A. P. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60041-6 · Cited by 159
Ekstrand, M. I., & Galter, D. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70811-9 · Cited by 151
Mitochondrial defect and PGC-1α dysfunction in parkin-associated familial Parkinson's disease
Pacelli, C., Rasmo, D. D., Signorile, A., Grattagliano, I., Tullio, G. D., D’Orazio, A., Nico, B., Comi, G. P., Ronchi, D., Ferranini, E., et al. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.12.022 · Cited by 132
Diabetes and Risk of Parkinson's Disease: An Updated Meta-Analysis of Case-Control Studies
Lü, L., Fu, D.-L., Li, H., Liu, A., Li, J.-H., & Zheng, G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085781 · Cited by 128
Lo, K. A., Labadorf, A. T., Kennedy, N. J., Han, M. S., Yap, Y. S., Matthews, B. J., Xin, X., Sun, L., Davis, R. J., Lodish, H. F., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.039 · Cited by 118
Association of PGC-1alphapolymorphisms with age of onset and risk of Parkinson's disease
Clark, J., Reddy, S., Zheng, K., Betensky, R. A., & Simon, D. K. (2011) · BMC Medical Genetics · doi:10.1186/1471-2350-12-69 · Cited by 114
Guo, Y., Xu, W., Liu, F., Li, J., Cao, X., Tan, L., Wang, J., & Yu, J. (2019) · Movement Disorders · doi:10.1002/mds.27665 · Cited by 105
Sajan, M. P., HANSEN, B. C., Ivey, R. A., Sajan, J., Ari, C., Song, S., Braun, U., Leitges, M., Higgs, M. G., & Farese, R. V. (2016) · Diabetes · doi:10.2337/db15-1428 · Cited by 91
Xu, Y., Deng, Y., & Qing, H. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13234 · Cited by 88
Endogenous alpha-synuclein influences the number of dopaminergic neurons in mouse substantia nigra
Garcia-Reitboeck, P., Anichtchik, O. V., Dalley, J. W., Ninkina, N. N., Tofaris, G. K., Buchman, V. L., & Spillantini, M. G. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.07.015 · Cited by 82
Polo-like kinases mediate cell survival in mitochondrial dysfunction
Matsumoto, T., Wang, P., Ma, W., Sung, H. J., Matoba, S., & Hwang, P. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904229106 · Cited by 76
Yang, S., Beavan, M. S., Chau, K., Taanman, J., & Schapira, A. H. V. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.01.011 · Cited by 73
Self-citationAlzheimer's disease could be “type 3 diabetes”
Pilcher, H. R. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70434-3 · Cited by 70
Li, J., Ma, W., Wang, P., Hurley, P. J., Bunz, F., & Hwang, P. M. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.05.022 · Cited by 48
Adipose-Derived Stem Cells: Methods for Isolation and Applications for Clinical Use
Mailey, B. A., Hosseini, A., Baker, J. L., Young, A., Alfonso, Z., Hicok, K. C., Wallace, A. M., & Cohen, S. R. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-1435-7_13 · Cited by 33
Nam, M., Han, J.-H., Jang, J.-Y., Yun, S.-E., Kim, G.-Y., Kang, S., & Rhim, H. (2015) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2015.09.006 · Cited by 13
Solmaz, V., Özlece, H. K., Eroğlu, H. A., Aktuğ, H., Erbaş, O., & Taşkıran, D. (2017) · Neurology Research International · doi:10.1155/2017/5952149 · Cited by 13
The Cytomegalovirus protein pUL37×1 targets mitochondria to mediate neuroprotection
Hong, C., Chau, K., & Schapira, A. H. V. (2016) · Scientific Reports · doi:10.1038/srep31373 · Cited by 10
Self-citation
Cited by
Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease
Nowell, J., Blunt, E., Gupta, D., & Edison, P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101979 · Cited by 179
“In diabetic mice models and an ex vivo experimental design, insulin resistance was associated with increased α -synuclein expression (Hong et al., 2020).”
Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances
Jiang, Q., Liu, J., Huang, S., Wang, X.-Y., Chen, X., Liu, G.-H., Ye, K., Song, W., Masters, C. L., Wang, J., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02145-7 · Cited by 165
Incretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease
Nowell, J., Blunt, E., & Edison, P. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01792-4 · Cited by 136
Diabetes and Cognitive Impairment: A Role for Glucotoxicity and Dopaminergic Dysfunction
Pignalosa, F. C., Desiderio, A., Mirra, P., Nigro, C., Perruolo, G., Ulianich, L., Formisano, P., Bèguinot, F., Miele, C., Napoli, R., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212366 · Cited by 136
GLP-1 Receptor Agonists: A New Treatment in Parkinson’s Disease
Kalinderi, K., Papaliagkas, V. T., & Fidani, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073812 · Cited by 130
Metadata
- Authors
- Hong, C.-T., Chen, K.-Y., Wang, W., Chiu, J.-Y., Wu, D., Chao, T.-Y., Hu, C.-J., Chau, K.-Y., & Bamodu, O.
- Affiliations
- Taipei Medical University-Shuang Ho Hospital (TW)
- Taipei Medical University (TW)
- Taipei Medical University Hospital (TW)
- UCL Queen Square Institute of Neurology (GB)
- Corresponding author
- Hong, Chien-Tai
- Bamodu, Oluwaseun
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2020-03-17
- Volume
- 9
- Issue
- 3
- Pages
- 740
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC7140619
- OpenAlex
- W3011296966
- Cited by
- 133
- References
- 55
- Citations by year
- 2026: 14 · 2025: 31 · 2024: 24 · 2023: 20 · 2022: 22 · 2021: 16 · 2020: 6
- FWCI
- 6.92
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UCL Discovery (University College London) (submittedVersion)
- Taipei Medical University Repository (submittedVersion)
- Funders
- Ministry of Science and Technology, Taiwan (105-2314-B-038-017, 106- 2314-B-038-023 MY3)
- Taipei Medical University (TMU105-AE1-B30)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- insulin resistance, Parkinson's disease, alpha-synuclein, PLK2, mitochondrial dysfunction, reactive oxygen species, dopaminergic neurons, PGC-1α, diabetes mellitus, neurodegeneration
- MeSH terms
- Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Animals, Diabetes Mellitus, Type 2, Humans, Insulin Resistance, Male, Mice, Inbred C57BL, Mitochondria, Models, Biological, Parkinson Disease, Phosphoserine, Tyrosine 3-Monooxygenase, Signal Transduction, Genome, Human, Protein Serine-Threonine Kinases, Reactive Oxygen Species, Disease Progression, alpha-Synuclein, Dopaminergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.